Recasting Listeria monocytogenes from Pathogen to Therapeutic Ally: A Commentary

Abstract

This commentary examines the recent preprint by Daula et al. on harnessing the virulence mechanisms of Listeria monocytogenes (Lm) for immunotherapeutic applications. The authors present a clear and well-integrated analysis of how Lm’s intrinsic pathogenic traits particularly its capacity for intracellular invasion, phagosomal escape, and robust antigen presentation can be repurposed to elicit potent antitumor responses. Their review of attenuation strategies, including genetic deletions and killed-but-metabolically-active constructs, highlights progress toward developing safe yet immunogenic Lm-based vectors. The discussion is strengthened by incorporation of early clinical trial data demonstrating feasibility and preliminary efficacy in cancers such as HPV-related and HER2-positive malignancies. Although challenges persist including verification of long-term safety, tumor microenvironmental suppression, and manufacturing scalability the preprint contributes meaningfully to the development of bacterial immunotherapy platforms. This commentary situates the work within the broader landscape of next-generation cancer immunotherapy and outlines future directions critical for advancing Lm-based therapeutic strategies.